News: Novo Nordisk A/S (NVO)

NVO on New York Consolidated

168.64USD
24 May 2013
Price Change (% chg)

$-0.28 (-0.17%)
Prev Close
$168.92
Open
$168.52
Day's High
$168.94
Day's Low
$167.12
Volume
191,504
Avg. Vol
283,012
52-wk High
$194.44
52-wk Low
$129.41

Search Stocks
Select another date:

Fri, May 24 2013

Novo obesity drug could launch in U.S. end 2014

COPENHAGEN - Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.

Continue Reading

UPDATE 1-Novo obesity drug could launch in U.S. end 2014

COPENHAGEN, May 24 - Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.

Novo sees US obesity drug launch end 2014/start of 2015-CSO

COPENHAGEN, May 24 - Denmark's Novo Nordisk said it expects to launch its liraglutide obesity treatment in the Unites States at the end of next year or start of 2015 after Phase III results late on Thursday confirmed weight loss in patients.

Novo Nordisk says obesity drug trial confirms weight loss

COPENHAGEN - Denmark's Novo Nordisk, the world's biggest insulin producer, said Phase III study results had shown people treated with its liraglutide drug had an 8 percent weight loss.

BRIEF-Novo Nordisk reports headline results for liraglutide trial

STOCKHOLM, May 23 - Novo Nordisk A/S : * Novo Nordisk A/S : Novo Nordisk reports 8% weight loss in phase 3a obesity

Novo Nordisk says completes hemophilia drug trial

COPENHAGEN - Denmark's Novo Nordisk, the world's biggest insulin producer, said on Friday it had completed the first phase III trial of a hemophilia drug, N9-GP.

UPDATE 3-NORDIC STOCKS - Factors to watch on May 17

(Adds Sanoma, Volvo, updates A.P. Moller-Maersk, FLSmidth)

Europe must pay up for new drugs: Novo Nordisk CEO

NEW YORK - Europe must start paying more for new medicines and take some of the cost burden of supporting pharmaceutical drug development off the United States, Novo Nordisk's Chief Executive Lars Sorensen said.

Novo's long-term targets hinge on two drugs: CEO

NEW YORK - Novo Nordisk's long-term profit targets are hanging in the balance after a big setback in the U.S. market but the Danish drugmaker may yet hit its goal if things work out for one of two drugs, its CEO said.

Sanofi says to step up development of new diabetes device

PARIS, May 2 - Sanofi is stepping up the development of a fixed combination of diabetes treatments Lantus and Lyxumia to sidestep an earlier setback with a similar pen device and take advantage of the delayed U.S. launch of competitor Novo Nordisk's new insulin.

Select another date:

Market Views

» More NVO Market Views

Press Releases

Search Stocks